摘要
目的观察重组人血管内皮抑素联合吉西他滨+顺铂方案(GP方案)治疗非小细胞肺癌的临床疗效。方法 53例非小细胞肺癌患者随机分为对照组(26例)和治疗组(27例)。对照组采用GP方案治疗;治疗组采用重组人血管内皮抑素联合GP方案治疗。治疗结束后观察两组治疗总有效率及不良反应。结果治疗组临床总有效率为66.7%,对照组临床总有效率为46.2%,差异有显著性(P<0.05);两组毒副反应比较差异无显著性差异(P>0.05)。结论重组人血管内皮抑素联合GP方案治疗非小细胞肺癌疗效显著,能明显改善患者的生活质量,值得临床推广应用。
Objective To observe the curative effects and adverse reactions of recombinant human endostatin combined with GP regimen in the treatment of non-small cell lung cancer（NSCLC）.Methods 53 cases of NSCLC were randomly divided into two groups： control group（26 cases） were treated with GP regimen,while treatment group（27 cases） were treated with combined therapy of recombinant human endostatin injection with GP.The total effective rate and adverse reaction was observed after treatment.Results The total effective rate was 66.7% in treatment group and 46.2% in control group;the difference was statistically significant（P0.05）.There was no difference between toxicity reaction of two groups（P0.05）.Conclusion The treatment of recombinant human endostatin combined with GP regimen has a good effect,can improve the life quality of NSCLC patients.It should be worthy of clinical applications.
出处
《临床肺科杂志》
2012年第5期869-870,共2页
Journal of Clinical Pulmonary Medicine
关键词
重组人血管内皮抑素
吉西他滨
顺铂
非小细胞肺癌
Recombinant human endostatin
Gemcitabine
Cisplatin
Non-small cell lung cancer
